|
(PQD3) The role and therapeutic potential of ZNF304 in Ovarian Cancer
|
5R21CA180145-02
|
$168,781
|
OZPOLAT, BULENT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
A Chemopreventive Strategy Based on Edible MicroRNAs Produced in Plants
|
1R03CA181895-01A1
|
$73,250
|
VANCE, VICKI
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
|
A novel soluble receptor-based therapy for Kidney Cancer
|
1R21CA178157-01A1
|
$172,369
|
WELFORD, SCOTT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer
|
5R01CA168900-03
|
$322,040
|
POWELL, DANIEL
|
UNIVERSITY OF PENNSYLVANIA
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
5K08CA160660-04
|
$156,330
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$2,555,132
|
Rosenberg, Steven
|
CCR (NCI)
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$613,610
|
Fry, Terry
|
CCR (NCI)
|
|
Adoptive transfer of gene-modified autologous T-cells post-ASCT for myeloma
|
5R01CA166961-03
|
$315,497
|
RAPOPORT, AARON
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$209,461
|
Kochenderfer, James
|
CCR (NCI)
|
|
An Integrated Nano-Cell Delivery Platform of Theranostics for Lung Cancers
|
5R01CA152005-05
|
$286,998
|
MOHAPATRA, SHYAM
|
UNIVERSITY OF SOUTH FLORIDA
|
|
Anti-pancreatic tumorigenesis by inactivation of SAG/RBX2 E3 ubiquitin ligase
|
5R21CA170995-02
|
$164,034
|
SUN, YI
|
UNIVERSITY OF MICHIGAN
|
|
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
|
5K08CA163941-03
|
$173,772
|
MOON, EDMUND
|
UNIVERSITY OF PENNSYLVANIA
|
|
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011413
|
$104,731
|
Kochenderfer, James
|
CCR (NCI)
|
|
Cancer Immunotherapy by Targeting A2 Adenosine Receptor
|
5R01CA111985-08
|
$207,975
|
SITKOVSKY, MICHAIL
|
NORTHEASTERN UNIVERSITY
|
|
Cancer Prevention and Treatment by Activation of a Brain-Adipocyte Axis
|
5R01CA166590-02
|
$309,460
|
CAO, LEI
|
OHIO STATE UNIVERSITY
|
|
Carolina Center of Cancer Nanotechnology Excellence
|
5U54CA151652-05
|
$2,415,854
|
DESIMONE, JOSEPH
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Cath B and uPAR si RNA constructs regressed glioma growth
|
5R01CA116708-10
|
$320,546
|
O'BRYAN, JOHN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
Cell Prep Core
|
ZIC BC 010905
|
$812,963
|
Wunderlich, John
|
CCR (NCI)
|
|
Cell Production Core Facility
|
ZIC BC 011569
|
$812,963
|
Somerville, Robert
|
CCR (NCI)
|
|
Center for Molecular Imaging Research at MGH/HMS
|
5P50CA086355-15
|
$1,392,802
|
WEISSLEDER, RALPH
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Center for Translational Cancer Nanomedicine
|
5U54CA151881-05
|
$2,407,041
|
TORCHILIN, VLADIMIR
|
NORTHEASTERN UNIVERSITY
|
|
Chronic Lymphocytic Leukemia Research Consortium
|
5P01CA081534-14
|
$3,769,923
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Clinical management of patients on immunotherapy protocols
|
ZID BC 011578
|
$5,425
|
Klebanoff, Christopher
|
CCR (NCI)
|
|
Clinical production of viral vectors for cancer gene therapy
|
ZIC BC 010989
|
$389,472
|
Feldman, Steven
|
CCR (NCI)
|
|
Clinical Scholars Biomedical Research Training Program
|
5T32CA009512-28
|
$277,007
|
KELLY, THOMAS
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Clinical Trials of Immunotherapies for Childhood Cancer
|
ZIA BC 011498
|
$776,987
|
Mackall, Crystal
|
CCR (NCI)
|
|
Combination Gene Therapy and Th1/Th2 Therapy
|
ZIA BC 011219
|
$267,157
|
Fowler, Daniel
|
CCR (NCI)
|
|
COMBINATORIAL-DESIGNED NANO-PLATFORMS TO OVERCOME TUMOR DRUG RESISTANCE
|
5U01CA151452-05
|
$400,638
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
Correcting Aberrant Splicing of the Human CD22 Gene
|
1R43CA177067-01A1
|
$225,000
|
MITCHELL, LLOYD
|
RETROTHERAPY, LLC
|
|
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia
|
5R01CA155367-04
|
$338,142
|
KORTYLEWSKI, MARCIN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Design of Oncolytic Adenovirus Conjugated with Novel Polymer for Cancer Treatment
|
5R01CA177932-02
|
$299,900
|
KIM, SUNG WAN
|
UNIVERSITY OF UTAH
|
|
Designing Lymph Nodes for Cancer Immunotherapy
|
5R01CA148995-05
|
$326,045
|
MULE, JAMES
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Developing Nanotechnology to Target HMGA1 in Pancreatic Cancer
|
1R03CA182679-01A1
|
$70,470
|
RESAR, LINDA
|
JOHNS HOPKINS UNIVERSITY
|
|
Development of Targeted Therapy for ERK Pathway in Breast Cancer
|
5R00CA139006-04
|
$241,530
|
BARTHOLOMEUSZ, CHANDRA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Dissecting Glioma Genesis through a Glial-Specific Mouse Model
|
5R01CA098503-09
|
$245,251
|
ZHANG, WEI
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Dual Role of E2F1 in Tumorigenesis
|
5R01CA079648-15
|
$326,672
|
JOHNSON, DAVID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Dual Targeted Nanoparticle therapy for Glioblastoma Multiforme
|
1U43CA182921-01
|
$224,980
|
GOOMER, RANDAL
|
AVRYGEN CORPORATION
|
|
Duke SPORE in Brain Cancer
|
1P50CA190991-01
|
$2,162,000
|
SAMPSON, JOHN
|
DUKE UNIVERSITY
|
|
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
|
1K99CA181491-01A1
|
$124,579
|
BALKO, JUSTIN
|
VANDERBILT UNIVERSITY
|
|
EGFR-targeted siRNA nanoparticles to treat NSCLC
|
N43CO130030-007
|
$1,000,000
|
UNGER, GRETCHEN
|
GENESEGUES INC
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
5K99CA172292-02
|
$126,228
|
ZHAO, JIANJUN
|
DANA-FARBER CANCER INST
|
|
Engineered tumor-specific T cells Resist Hypoxic-Tumor Immunosuppressive Attacks.
|
5R01CA142664-05
|
$299,690
|
YOTNDA, PATRICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Engineering Polymers for Gene Therapy of Head Cancer
|
5R01CA107621-09
|
$308,161
|
GHANDEHARI, HAMID
|
UNIVERSITY OF UTAH
|
|
Enhancing Delivery and Regulating Gene Expression in Oncolytic Vaccinia Vectors
|
5R01CA140215-05
|
$295,784
|
THORNE, STEPHEN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity
|
5R01CA114425-08
|
$294,269
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells
|
1R01CA181598-01A1
|
$318,513
|
GILBOA, ELI
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Enhancing T Cell Therapy of Cancer
|
5P01CA094237-12
|
$1,874,319
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Enhancing Viral Oncolysis with Vasculostatin Gene Delivery
|
5R01CA150153-04
|
$395,103
|
KAUR, BALVEEN
|
OHIO STATE UNIVERSITY
|
|
Evaluation of Vectors based on group B adenoviruses
|
5R01CA144057-10
|
$319,059
|
LIEBER, ANDRE
|
UNIVERSITY OF WASHINGTON
|
|
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer
|
3R01CA140323-05S1
|
$84,070
|
GODWIN, ANDREW
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|